Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259882 | 0.88 | ALDH1A1 (0.70) | LMNATSHRALDH1A1PKMMAPT | |
| SCHEMBL229421 | 0.86 | HPGD (0.55) | LMNATSHRALDH1A1MAPTTP53 | |
| SCHEMBL15455520 | 0.86 | ALDH1A1 (0.53) | LMNATSHRALDH1A1MAPTTP53 | |
| SCHEMBL1744039 | 0.86 | MAPT (0.48) | LMNATSHRALDH1A1PKMMAPT | |
| SCHEMBL4255401 | 0.86 | ALDH1A1 (0.67) | LMNATSHRALDH1A1PKMMAPT | |
| SCHEMBL3005944 | 0.83 | ALDH1A1 (0.67) | LMNATSHRALDH1A1PKMMAPT | |
| SCHEMBL2742309 | 0.83 | TSHR (0.57) | LMNATSHRALDH1A1MAPTTP53 | |
| SCHEMBL2742310 | 0.83 | TSHR (0.67) | LMNATSHRALDH1A1MAPTTP53 | |
| SCHEMBL2742302 | 0.83 | ALDH1A1 (0.73) | LMNATSHRALDH1A1POLBNPSR1 | |
| SCHEMBL231034 | 0.82 | ALDH1A1 (0.55) | TSHRALDH1A1MAPTTP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359362-B2 | Triazolo and tetrazolo pyrimidine derivatives as HNE inhibitors for treating COPD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| US-9359362-B2 | Triazolo and tetrazolo pyrimidine derivatives as HNE inhibitors for treating COPD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| US-20140038988-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038988-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-8569314-B2 | Triazolo and tetrazolo pyrimidine derivatives as HNE inhibitors for treating COPD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8569314-B2 | Triazolo and tetrazolo pyrimidine derivatives as HNE inhibitors for treating COPD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8569314-B2 | Triazolo and tetrazolo pyrimidine derivatives as HNE inhibitors for treating COPD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| EP-2385945-B1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER IP GMBH (DE) | 2013-01-23 | — | — | EP | disclosed |
| US-20120004203-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20120004203-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20120004203-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-05 | — | — | US | disclosed |
| WO-2010078953-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038988-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | KEAP1, NOX4, NOX5 | LMNA 2053/4885TSHR 3372/4885ALDH1A1 197/4885 |
| US-20120004203-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | KEAP1, NOX4, NOX5 | LMNA 2053/4885TSHR 3372/4885ALDH1A1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.